| |
3 & 4 Oral IFN-Free Roche HCV Regimens Studies, Treatment Naïve or Null Responders: setrobuvir+mericitabine+danoprevir/r+rbv. ANNAPURNA Study...
|
| |
| |
setrobuvir is their non-nucleoside polymerase inhibitor acquired from Anadys ANA598
ANA598 HCV Polymerase Inhibitor Safety & Activity monotherapy + Peg/Rbv in Genotype 1
http://www.natap.org/2010/EASL/EASL_20.htm
ANA-598 HCV Non-Nuke Phase 2b Study Preliminary Data Results Background to Phase IIb Study
http://www.natap.org/2011/HCV/101411_01.htm
72% OF PATIENTS RECEIVING ANA598 IN PHASE II - NATAP
www.natap.org/2010/EASL/EASL_19.htm
SAN DIEGO, April 15, 2010 -- Anadys Pharmaceuticals, Inc. announced today that 72% of hepatitis C patients receiving ANA598 400 mg twice daily (bid) plus
Mericitabine (R7128)
INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS - (04/24/12)
Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside HCV RNA Polymerase Inhibitor, Following Multiple, Ascending, Oral Doses in Patients with HCV Genotype 1 Infection Who have Failed Prior Interferon Therapy - (11/7/07)
No evidence of drug resistance or baseline S282T resistance mutation among GT 1 and GT 4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN/RBV combination treatment for up to 12 weeks: Interim analysis from the PROPEL study - (11/21/10)
SVR24 AMONG G1/4 TREATMENT-NAIVE PATIENTS RECEIVING MERICITABINE IN COMBINATION WITH PEG-IFNα-2A/RBV: FINAL ANALYSIS FROM THE JUMP-C STUDY - (04/24/12)
ANNAPURNA: A Study of The Combination of RO5466731 ...4 oral HCV drugs IFN-free in gt1a & 1b clinicaltrials.gov/ct2/show/NCT01628094
Jun 22, 2012 - This randomized, open-label, multicenter study will evaluate the safety , efficacy and tolerability of the combination treatment RO5466731
ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment
This study is currently recruiting participants.
Verified August 2012 by Hoffmann-La Roche
Randomized, Open-Label, Multicenter Study of Safety, Efficacy, and Tolerability of the Combination of RO5466731, RO5190591, Ritonavir, and Copegus With or Without RO5024048 in HCV Genotype 1 Infected Patients Who Are Either Treatment Naïve or Null Responders to Previous Interferon-Based Treatment
|
|
| |
| |
|
|
|
